BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16516313)

  • 1. Pharmacologic approaches to rhythm versus rate control in atrial fibrillation--where are we now?
    Wyse DG
    Int J Cardiol; 2006 Jun; 110(3):301-12. PubMed ID: 16516313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of atrial fibrillation.
    Hersi A; Wyse DG
    Curr Probl Cardiol; 2005 Apr; 30(4):175-233. PubMed ID: 15778690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial fibrillation: rhythm control offers no advantage over rate control for some, but not all.
    Li YB; Hu CL; Liu J; Chen YX; Qu Z; Xu JL; Chen JB; Wan J; Tang QZ; Huang CX
    Med Hypotheses; 2007; 69(1):206-8. PubMed ID: 17011138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
    de Denus S; Sanoski CA; Carlsson J; Opolski G; Spinler SA
    Arch Intern Med; 2005 Feb; 165(3):258-62. PubMed ID: 15710787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
    Talajic M; Roy D
    Can J Cardiol; 2005 Sep; 21 Suppl B():19B-25B. PubMed ID: 16239983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
    Singla S; Karam P; Deshmukh AJ; Mehta J; Paydak H
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):12-20. PubMed ID: 21335483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate versus rhythm control in atrial fibrillation.
    Anthony KK; Mauro VF
    Ann Pharmacother; 2004 May; 38(5):839-44. PubMed ID: 15039475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AFFIRM and RACE trials: implications for the management of atrial fibrillation.
    Blackshear JL; Safford RE; ;
    Card Electrophysiol Rev; 2003 Dec; 7(4):366-9. PubMed ID: 15071255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Curtis AB; Gersh BJ; Corley SD; DiMarco JP; Domanski MJ; Geller N; Greene HL; Kellen JC; Mickel M; Nelson JD; Rosenberg Y; Schron E; Shemanski L; Waldo AL; Wyse DG;
    Am Heart J; 2005 Apr; 149(4):645-9. PubMed ID: 15990747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation: the rate versus rhythm management controversy.
    Camm AJ; Savelieva I
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():23-34. PubMed ID: 22518391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate versus rhythm control in the management of patients with atrial fibrillation.
    Pelargonio G; Prystowsky EN
    Nat Clin Pract Cardiovasc Med; 2005 Oct; 2(10):514-21. PubMed ID: 16186849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.
    Chung MK; Shemanski L; Sherman DG; Greene HL; Hogan DB; Kellen JC; Kim SG; Martin LW; Rosenberg Y; Wyse DG;
    J Am Coll Cardiol; 2005 Nov; 46(10):1891-9. PubMed ID: 16286177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study.
    Curtis AB; Seals AA; Safford RE; Slater W; Tullo NG; Vidaillet H; Wilber DJ; Slee A
    Am Heart J; 2005 Feb; 149(2):304-8. PubMed ID: 15846269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous amiodarone for conversion of atrial fibrillation: misled by meta-analysis?
    Slavik RS; Zed PJ
    Pharmacotherapy; 2004 Jun; 24(6):792-8. PubMed ID: 15222670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacologic maintenance of sinusal rhythm and/or control of the ventricular response in patients with atrial fibrillation or flutter].
    López Gil M; Arribas F; Hernández Afonso J; Angel Santos M; García-Cosío F
    Rev Esp Cardiol; 1996; 49 Suppl 2():32-41. PubMed ID: 8755694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of atrial fibrillation].
    Fazekas T; Csanádi Z; Varró A
    Orv Hetil; 2003 Jun; 144(24):1199-206. PubMed ID: 12866149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiarrhythmic drugs in paroxysmal atrial fibrillation. When and how?].
    Lévy S; Ricard P; Yapo F; Mansouri C
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():19-24. PubMed ID: 8734159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of initial resting ventricular rate to the ability to achieve and maintain normal sinus rhythm in patients with atrial fibrillation.
    Cooper HA; Sacco J; Solomon AJ; Feld GK; Leman R; Wilber D;
    Am J Cardiol; 2005 Mar; 95(5):597-602. PubMed ID: 15721098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation and heart failure comorbidity.
    Schuchert A
    Minerva Cardioangiol; 2005 Aug; 53(4):299-311. PubMed ID: 16177674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.